International Experience in Therapeutic Value and Value-Based Pricing: A Rapid Review of the Literature
| Autor: | Pieralessandro Lasalvia, L. Prieto-Pinto, Camilo Castañeda-Cardona, Nathaly Garzón-Orjuela, Diego Rosselli |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Value (ethics)
Internationality Cost Control media_common.quotation_subject Economics Econometrics and Finance (miscellaneous) MEDLINE Scopus Exploratory research Drug Costs 03 medical and health sciences 0302 clinical medicine Value-based pricing Humans Value-Based Health Insurance 030212 general & internal medicine Pharmacology Toxicology and Pharmaceutics (miscellaneous) Reimbursement Pharmaceutical industry media_common Actuarial science business.industry 030503 health policy & services Health Policy Negotiation Therapeutic Uses 0305 other medical science business |
| Zdroj: | Value in Health Regional Issues. 23:37-48 |
| ISSN: | 2212-1099 |
| DOI: | 10.1016/j.vhri.2019.11.008 |
| Popis: | Objectives To characterize at a global level the concept of therapeutic value (TV) and describe the experience of value-based pricing (VBP) policies in 6 reference countries. Methods We conducted a rapid review of the literature that addressed 2 exploratory research questions. A systematic and exhaustive search was carried out up to July 2018 in MEDLINE (Ovid), Embase, Scopus, and Web of Science. Results The concepts of TV and VBP are related; value frameworks for medicines should include social preferences, comparative effectiveness, safety, adoption viability, social impact, high quality of evidence, severity of illness, and innovation. The added therapeutic value (ATV) is the manner of measuring the therapeutic advantages of new medicines compared with existing ones in terms of comparative effectiveness and safety. There are variations in the mechanisms of reimbursement and drug pricing regulation between the countries of study. Conclusion In a VBP system it is essential to establish the TV and ATV of a new medicine. Although there are no methodological guidelines for the implementation of VBP policies, the process implies from the beginning the definition of TV categories that will be included in the drug pricing and reimbursement systems. Agreements between the pharmaceutical industry and governments have become a useful tool as a negotiating mechanism in most countries. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect